Abstract
In this surgical series of 100 pheochromocytomas (PH), where 91 cases were studied and followed up, the frequency of malignancy appears high (29%) on macroscopic criteria observed at the first operation (25 out 26 cases of malignant PH) or thanks to the occurence of metastases (1 case out of 26 malignant PH). While some clinical signs are suggestive, there is no excretory profile predictive of malignancy. Isolated or predominant secretion of dopamine is not specific of malignancy event if it occurs more frequently and severely in malignant PH. Bilateral involvement, occurring in the setting of phacomatosis or of multiple endocrine neoplasia (MEN II), or in a sporadic case, is not a predictor for malignancy. Contrarily, extraadrenal involvement is a major feature indicative of malignancy. A CT scan which demonstrates possible locoregional invasion, and a MIGB scan revealing distant localizations raise the suspicion of malignancy. The preferred surgical approach is via a laparotomy, thus allowing the exploration of all possible abdominal chromaffin site and the search for intraabdominal metastases. Intraoperative MIBG scanning checks the completeness of the excision. Flow cytometric DNA ploidy studies have been performed in 25 of our patients. The follow up of benign or malignant PH, after excision “for cure” must be life-long: clinically, biologically and by MIGB scan. Persistence of the disease after surgery or recurrence with unresectable metastases can benefit from MIGB and chemotherapy.
Similar content being viewed by others
References
Linnoila R.I., Keiser H.R., Steinberg S.M., Lack E.E. Histopathology of benign versus malignant sympathoadrenal paragangliomas: Clinicopathologic study of 120 cases including unusual histologic features. Hum. Pathol. 21:1168, 1990.
Hosaka Y., Rainwater L.M., Grant C.S., Farrow G.M., Van Heerden J.A., Lieber M.M. Pheochromocytoma: Nuclear deoxyribonucleic acid pattern by flow cytometry. Surgery 100:1003, 1986.
Mornex R., Berthezene F., Peyrin L., Tran Minh V., Martin J.P., Fulchiron D. Phéochromocytomes malins. Arch. Mal. Coeur 72:96, 1979.
Hauss J., Pircher W., Spiegel H.U., Kertelge E., Roessner A., Vetter H. Pheochromozytombehandlung: Wandel von Diagnostik und Therapie. Acta Med. Austr. 4:95, 1988.
Badet C. Fr Les phéochromocytomes malins. Etude de 14 observations. Revue de la littérature Thèse Lyon, 1990. University of Lyon, Ed., Lyon.
Thompson N.W., Alio M.D., Shapiro B., Sisson J.C., Beierwaltes W. Extra adrenal and metastatic pheochromocytoma: the role of 131 I metaiodobenzylguanidine (131 IMIBG) in localisation and management. World J. Surg. 8:605, 1984.
Proye C., Vérin P., Sautier M., Thevenin D., Fontaine P., Vantyghem M.C., Wemeau J.L. Expérience de 60 interventions pour phéochromocytome. Rev. Franc. End. Clin. 30:291, 1989.
Scott H.W. Jr., Halter S.A. Oncologic aspects of pheochromocytoma: the importance of follow up. Surgery 96:1061, 1984.
Tison E., Fontaine P., Cantineau D., Vantyghem M.C., Lecomte-Houcke M., Proye C., Lefebvre J. Phéochromocytome et maladie de von Hippel Lindau. A propos d’un cas avec revue de la littérature. Sem Hôp Paris 65:941, 1989.
Tison E., Marchand X., Kacet S., Proye C., Lekieffre J. Phéochromocytome malin associé à une maladie de Recklinghausen. A propos d’un cas. Ann. Cardiol. Angéiol. 35:551, 1986.
Van Heerden J.A., Roland C.F., Carnery A., Sheps S.G., Grant C.S. Long term evaluation following resection of apparently benign pheochromocytomas/paragangliomas. World J. Surgery 14:325, 1990.
Proye C., Fossati P., Fontaine P., Lefebvre J., Decoulx M., Wemeau J.L., Dewailly D., Rwamasirabo E., Cecat P. Dopamine secreting pheochromocytoma. An unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery 100:1154, 1986.
Fontaine P., Romon M., Dewailly D., Veret E., Racadot-Leroy N., Proye C., Fossati P. Le phéochromocytome à dopamine. Rev. Franc. End. Clin. (Paris) 26:41, 1985.
Fossati P., Romon-Rousseaux M., Racadot A., Racadot-Leroy N., Proye C., Wemeau J.L., Bethouart M., Mazucca M. Le phéochromocytome à dopamine. Presse Med. 11:1607, 1982.
Goldstein D.S., Stull R., Eisenhofer G., Sisson J., Weder A., Averbuch S.D., Keiser H.R. Plasma 3–4 dihydroxphenylalanine (Dopa) and catecholamines in neuroblastoma and pheochromocytoma. Ann. Intern. Med. 705:887, 1986.
Tippe P.A., Mc Ewan A.J., Acrery D.M. A reevaluation of dopamine excretion in pheochromocytoma. Clin. Endocrinol. (Oxf.) 25:401, 1986.
Serrano P.A., Chavez-Laba B., Sanchez-Torres G. Dopamine excretion in benign pheochromocytoma. Biomedicine 29: 229, 1978.
Vinik A.I., Shapiro B., Thompson N.W. Plasma gut hormone levels in 37 patients with pheochromocytomas. World J. Surgery 10:593, 1986.
Proye C., Fossati P., Lefebvre J., Decoulx M., Wemeau J.L., Fontaine P., Rwamasirabo E., Richardson A.J.C. La malignité d’un phéochromocytome est-elle prévisible. A propos de 50 patients opérés. Lyon Chir. 83: 98, 1987.
Heath H., Edis A.J. Pheochromocytoma associated with hyperalcemia and ectopic secretion of calcitonin. Ann. Intern. Med. 91:208, 1979.
Altergott R., Barbato A., Lawrence C.A., Paloyan E., Freeark R.J., Prinz R.A. Spectrum of catecholamine secreting tumours of the organ of Zuckerkandel. Surgery 98:1121, 1985.
Scott Jr., H.W., Reynolds V., Green N., Page D., Oates I.A., Robertson D., Roberts S. Clinical experience with malignant pheochromocytoma. SGO 154:801, 1982.
Michel F., Gattegno B., Sicard J.F., Rolan J., Thibaut P. A propos d’une observation de phéochromocytome vésical malin. Conduite diagnostique et thérapeutique. Ann. Urol. 24:396, 1990.
Ochi K., Yostllora S., Morita M., Tarenchi M. Phechromocytoma of the bladder. Urology 17:228, 1981.
Das S., Lowe P. Malignant pheochromocytoma of the bladder. J. Urol. 123: 282, 1980.
Chatal J.F., Charbonnel B. Comparaison de la scintigraphie à la MIBG et de la tomodensitométrie pour localiser les phéochrocytomes. Ann. Endocrinol. (Paris) 46:125, 1985.
Gough I.R., Thompson N.W., Shapiro B., Sisson J.C. Limitations of 131 I-MIBG scintigraphy in locating pheochromocytomas. Surgery 90:115, 1985.
Shapiro B., Copp J.E., Sisson J.C., Eyre P.L., Wallis J., Beierwaltes W.H. Iodine 131 MIBG for the locating of suspected pheochromocytoma. Experience in 400 cases. J. Nucl. Med. 26:576, 1985.
Swensen S.J., Brown M.L., Sheps S.G., Siezmore G.W., Gharis H., Grant C.S., Van Heerden I. Use of 131 I-MIBG Scintigraphy in the evaluation of suspected pheochromocytoma. Mayo Clin. Proc. 60: 299, 1985.
Proye C., Thevenin D., Cecat P., Petillot P., Carnaille B., Vérin P., Sautier M., Racadot N. Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: Hemodynamics and free catecholamine assays in 41 consecutive patients. Surgery 106:1149, 1989.
Cullen M.L., Staren E.D., Strauss A.R., Doolas A., Shah R., Patel S., Economou S.G. Pheochromocytoma: operative strategy. Surgery 98: 927, 1985.
Irvin G.L. III, Fishman L.M., Sher J.A., Yeung L.K., Irani H. Pheochromocytoma. Lateral versus anterior operative approach. Ann. Surg. 209:774, 1989.
Schroder H.D., Johannsen L. Demonstration of S 100 protein in sustentacular cells of pheochromocytomas and paragangliomas. Histopathology 10:1023, 1986.
Hassoun J., Monges G., Giraud P., Henry J.F., Charpin C., Payan H., Toga M. Immunohistological study of phheochromocytomas. An investigation of Methionin-Enkephalin, Vasoactiv intestinal peptide, Somatostatin corticotropin, Endorphin and Calcitonin in 16 tumors. Am. J. Pathol. 114:56, 1984.
Lloyd R.V., Shapiro B., Sisson J.C., Kalff V., Thompson N.N., Beierwaltes W.D. An immunohistochemical study of pheochromocytomas. Arch. Pathol. Lab. Med. 108:541, 1984.
Abemayor E., Harken A.H., Koop C.E. Multiple sequential pulmonary resections for metastatic pheochromocytoma with long term survival. Am. J. Surg. 140:696, 1980.
Brennan M.F., Keiser A.R. Persitent and recurrent pheochromocytoma: the role the surgery. World J. Surg. 6:397, 1982.
Averbuch S.D., Steadkley C.S., Young R.C., Gelmann E.P., Golstein D.S., Stull R.S., Keiser H.R. Malignant pheochromocytoma: Effective treatment with a combination of Cyclophosphamide, Vincristine, and Dacabarine. Ann. Intern. Med. 109:267, 1988.
Charbonnel B., Chatal J.F., Brendel A.J., Lanehche B., Lumbroso J., Marchandise X., Mornex R., Schlumberger M., Wemeau J.L. Le traitement des phéochromocytomes malins par la 131 I-Métaiodobenzylguanidine. Ann. Endocrinol. (Paris) 49:344, 1988.
Decoulx M., Wemeau J.L., Racadot-Leroy N., Grimbert I., Proye C., Plane C. L’alpha méthyl paratyrosine dans le traitement des phéochromocytomes malins. Rev. Med. Int. 8:383, 1987.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Proye, C., Vix, M., Goropoulos, A. et al. High incidence of malignant pheochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991. J Endocrinol Invest 15, 651–663 (1992). https://doi.org/10.1007/BF03345810
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345810